ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.

Hayashi H, Tatsumi K, Katada H, Matsuda Y, Tsunenari T, Honda M, Nemoto T, Shimizu S, Miura-Okuda M, Ikuta Y, Ito A, Ogami C, Kato C, Kamimura M, Kibayashi T, Kubo C, Komatsu S, Komori Y, Shinozuka J, Susumu H, Tanno H, Tomii Y, Nakagawa K, Nagano H, Nanami M, Nishito Y, Fujisawa N, Matsushita T, Michisaka S, Yamazaki M, Yoshimoto M, Wakatsuki H, Wakabayashi T, Wada NA, Ueda O, Konishi H, Kashima K, Tanaka H, Endo M, Kitazawa T, Sakaguchi S, Kamata-Sakurai M, Igawa T.

Open source

DOI
10.1136/jitc-2025-013397
Published
2026-01-09
Container
J Immunother Cancer
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2025-013397,
  title = {ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.},
  author = {Hayashi H and  Tatsumi K and  Katada H and  Matsuda Y and  Tsunenari T and  Honda M and  Nemoto T and  Shimizu S and  Miura-Okuda M and  Ikuta Y and  Ito A and  Ogami C and  Kato C and  Kamimura M and  Kibayashi T and  Kubo C and  Komatsu S and  Komori Y and  Shinozuka J and  Susumu H and  Tanno H and  Tomii Y and  Nakagawa K and  Nagano H and  Nanami M and  Nishito Y and  Fujisawa N and  Matsushita T and  Michisaka S and  Yamazaki M and  Yoshimoto M and  Wakatsuki H and  Wakabayashi T and  Wada NA and  Ueda O and  Konishi H and  Kashima K and  Tanaka H and  Endo M and  Kitazawa T and  Sakaguchi S and  Kamata-Sakurai M and  Igawa T.},
  year = {2026},
  journal = {J Immunother Cancer},
  doi = {10.1136/jitc-2025-013397},
  url = {https://doi.org/10.1136/jitc-2025-013397}
}

RIS

TY  - JOUR
TI  - ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.
AU  - Hayashi H
AU  -  Tatsumi K
AU  -  Katada H
AU  -  Matsuda Y
AU  -  Tsunenari T
AU  -  Honda M
AU  -  Nemoto T
AU  -  Shimizu S
AU  -  Miura-Okuda M
AU  -  Ikuta Y
AU  -  Ito A
AU  -  Ogami C
AU  -  Kato C
AU  -  Kamimura M
AU  -  Kibayashi T
AU  -  Kubo C
AU  -  Komatsu S
AU  -  Komori Y
AU  -  Shinozuka J
AU  -  Susumu H
AU  -  Tanno H
AU  -  Tomii Y
AU  -  Nakagawa K
AU  -  Nagano H
AU  -  Nanami M
AU  -  Nishito Y
AU  -  Fujisawa N
AU  -  Matsushita T
AU  -  Michisaka S
AU  -  Yamazaki M
AU  -  Yoshimoto M
AU  -  Wakatsuki H
AU  -  Wakabayashi T
AU  -  Wada NA
AU  -  Ueda O
AU  -  Konishi H
AU  -  Kashima K
AU  -  Tanaka H
AU  -  Endo M
AU  -  Kitazawa T
AU  -  Sakaguchi S
AU  -  Kamata-Sakurai M
AU  -  Igawa T.
PY  - 2026
JO  - J Immunother Cancer
DO  - 10.1136/jitc-2025-013397
UR  - https://doi.org/10.1136/jitc-2025-013397
ER  -

APA

H, H., K, T., H, K., Y, M., T, T., M, H., T, N., S, S., M, M., Y, I., A, I., C, O., C, K., M, K., T, K., C, K., S, K., Y, K., J, S., H, S., H, T., Y, T., K, N., H, N., M, N., Y, N., N, F., T, M., S, M., M, Y., M, Y., H, W., T, W., NA, W., O, U., H, K., K, K., H, T., M, E., T, K., S, S., M, K., & T., I. (2026). ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.. J Immunother Cancer. https://doi.org/10.1136/jitc-2025-013397

Source records